- Home
- INZY vs CLAR Comparison
INZY vs CLAR Comparison
Compare INZY & CLAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INZY
- CLAR
- Stock Information
- Founded
- INZY 2015
- CLAR 1957
- Country
- INZY United States
- CLAR United States
- Employees
- INZY N/A
- CLAR N/A
- Industry
- INZY Biotechnology: Pharmaceutical Preparations
- CLAR Recreational Games/Products/Toys
- Sector
- INZY Health Care
- CLAR Consumer Discretionary
- Exchange
- INZY Nasdaq
- CLAR Nasdaq
- Market Cap
- INZY 188.2M
- CLAR 173.0M
- IPO Year
- INZY 2020
- CLAR N/A
- Fundamental
- Price
- INZY $2.00
- CLAR $4.37
- Analyst Decision
- INZY Strong Buy
- CLAR Strong Buy
- Analyst Count
- INZY 7
- CLAR 3
- Target Price
- INZY $16.43
- CLAR $6.33
- AVG Volume (30 Days)
- INZY 666.9K
- CLAR 211.4K
- Earning Date
- INZY 11-05-2024
- CLAR 03-06-2025
- Dividend Yield
- INZY N/A
- CLAR 2.27%
- EPS Growth
- INZY N/A
- CLAR N/A
- EPS
- INZY N/A
- CLAR 0.13
- Revenue
- INZY N/A
- CLAR $269,413,000.00
- Revenue This Year
- INZY N/A
- CLAR N/A
- Revenue Next Year
- INZY N/A
- CLAR $9.30
- P/E Ratio
- INZY N/A
- CLAR $34.84
- Revenue Growth
- INZY N/A
- CLAR 48.98
- 52 Week Low
- INZY $1.97
- CLAR $3.89
- 52 Week High
- INZY $7.80
- CLAR $7.55
- Technical
- Relative Strength Index (RSI)
- INZY 33.08
- CLAR 45.33
- Support Level
- INZY $2.68
- CLAR $4.36
- Resistance Level
- INZY $3.18
- CLAR $4.78
- Average True Range (ATR)
- INZY 0.23
- CLAR 0.19
- MACD
- INZY -0.01
- CLAR -0.02
- Stochastic Oscillator
- INZY 2.52
- CLAR 33.33
About INZY Inozyme Pharma Inc.
Inozyme Pharma Incclinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of diseases impacting the vasculature, soft tissue, and skeleton. The company is pursuing the development of therapeutics to address the underlying causes of these debilitating diseases. The company is focused on developing a novel therapy to treat the rare genetic diseases of ENPP1 and ABCC6 Deficiencies. The company product candidate, INZ-701, is a soluble, recombinant, genetically engineered, fusion protein that is designed to correct a defect in a pathway involving ENPP1 and ABCC6 Deficiencies.
About CLAR Clarus Corporation
Clarus Corp is a designer, developer, manufacturer, and distributor of outdoor equipment and lifestyle products focused on the climb, ski, mountain, sport, and skincare markets. The company operates through the Outdoor segment, which includes Black Diamond Equipment and PIEPS, is a global leader in designing, manufacturing, and marketing innovative outdoor engineered equipment and apparel for climbing, mountaineering, trail running, backpacking, skiing, and a wide range of other year-round outdoor recreation activities. The Adventure segment, which includes Rhino-Rack, MAXTRAX and TRED, is a manufacturer of highly-engineered automotive roof racks, trays, mounting systems, luggage boxes, carriers, recovery boards and accessories in Australia and New Zealand and United States.